Evidence map›Paper›PMID 36158701›Full record

ArticleFrontiers in oncology2022

Broad genomic workup including optical genome mapping uncovers a

Verena Nilius-Eliliwi, Marco Tembrink, Wanda Maria Gerding, Krzystof P Lubieniecki, Joanna M Lubieniecka, Stefanie Kankel, Thomas Liehr, Thomas Mika, Fotios Dimopoulos, Konstanze Döhner and 3 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. NovelCancers · 2023
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Verena Nilius-EliliwiDepartment of Medicine, Hematology and Oncology, Knappschaftskrankenhaus, Ruhr-University Bochum, Bochum, Germany.
Marco TembrinkHuman Genetics, Ruhr-University Bochum, Bochum, Germany.
Wanda Maria GerdingHuman Genetics, Ruhr-University Bochum, Bochum, Germany.
Krzystof P LubienieckiHuman Genetics, Ruhr-University Bochum, Bochum, Germany.
Joanna M LubienieckaHuman Genetics, Ruhr-University Bochum, Bochum, Germany.
Stefanie KankelJena University Hospital, Friedrich Schiller University, Institute of Human Genetics, Jena, Germany.
Thomas LiehrJena University Hospital, Friedrich Schiller University, Institute of Human Genetics, Jena, Germany.
Thomas MikaDepartment of Medicine, Hematology and Oncology, Knappschaftskrankenhaus, Ruhr-University Bochum, Bochum, Germany.
Fotios DimopoulosDepartment of Medicine, Hematology and Oncology, Knappschaftskrankenhaus, Ruhr-University Bochum, Bochum, Germany.
Konstanze DöhnerDepartment of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
Roland SchroersDepartment of Medicine, Hematology and Oncology, Knappschaftskrankenhaus, Ruhr-University Bochum, Bochum, Germany.
Hoa Huu Phuc NguyenHuman Genetics, Ruhr-University Bochum, Bochum, Germany.
Deepak Ben VangalaDepartment of Medicine, Hematology and Oncology, Knappschaftskrankenhaus, Ruhr-University Bochum, Bochum, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In acute myeloid leukemia (AML), treatment decisions are currently made according to the risk classification of the European LeukemiaNet (ELN), which is based on genetic alterations. Recently, optical genome mapping (OGM) as a novel method proved to yield a genome-wide and detailed cytogenetic characterization at the time of diagnosis. A young female patient suffered from a rather unexpected aggressive disease course under FLT3 targeted therapy in combination with induction chemotherapy. By applying a "next-generation diagnostic workup" strategy with OGM and whole-exome sequencing (WES), a

Indexed as

acute myeloid leukemiaARPP21biphenotypic leukemiaDDX3XFLT3-ITDMLLT10optical genome mappingSUZ12

Identifiers

PMID36158701
PMCPMC9501710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.